BridgeBio Oncology Therapeutics, Inc. (BBOT)
NGM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (49.2M) | (43.4M) | (46.2M) | (60.2M) |
| Net Income | (44.8M) | (38.8M) | (42.1M) | (56.5M) |
| Diluted EPS | $-1.03 | $-0.49 | $-526.11 | $-705.20 |
Annual Financials
| Metric | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Operating Income | (64.8M) | (80.9M) | (145.8M) |
| Net Income | (64.7M) | (74.3M) | (134.0M) |
| Diluted EPS | $-0.82 | $-0.94 | N/A |